Fatty liver. Nonalcoholic fatty liver disease [NAFLD]?Central haemorrhagic necrosis of liver?Infarction of liver?Hepatorenal syndrome?Chronic passive congestion of liver
Conditions
Interventions
Intervention 1: Intervention group: People in this group receive capsules containing chitosan, with a dose of 500 mg, 6 pieces per day, 2 pieces half an hour before each main meal (breakfast, lunch, d
Sponsors
Khoram-Abad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age 18 to 65 years Diagnosis of fatty liver grade one and two Filling the informed consent form by the individual Not during pregnancy and breastfeeding. Do not have morbid obesity (body mass index greater than 40 Do not have a history of consuming more than 20 grams of alcohol per day for women and more than 30 grams per day for men. Suffering from any type of immune disorder including: autoimmune disorders, cancer, human immunodeficiency virus (HIV) Do not suffer from liver or kidney failure, other liver diseases such as hepatitis, alcoholic fatty liver. Do not use hepatotoxic drugs such as sodium valproate. Do not have a history of food allergy to marine products and herbal supplements or chitosan. Do not have a history of bariatric surgery to lose weight
Exclusion criteria
Exclusion criteria: Pregnancy and breastfeeding Morbid obesity (body mass index greater than 40) History of alcohol consumption (more than 20 grams per day for women and more than 30 grams per day for men), Having any type of immune disorder, including: autoimmune disorders, cancer, human immunodeficiency virus (HIV) Suffering from liver or kidney failure, other liver diseases such as hepatitis, alcoholic fatty liver Taking hepatotoxic drugs such as sodium valporate History of food allergy to chitosan and herbal supplements History of bariatric surgery for weight loss Hypothyroidism, diabetes, high blood pressure, diet, medications and weight loss supplements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of hepatic steatosis at the beginning and end of the study is measured by elastography as the primary outcome. Timepoint: The beginning and end of the study. Method of measurement: It is measured by elastography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Status of receiving food. Timepoint: At the beginning, during the study and at the end of the study, it is measured and checked. Method of measurement: Remembered 3 days of food. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Ebrahim Fallahi
Khoram-Abad University of Medical Sciences
Outcome results
None listed